News AZ tried to buy Daiichi Sankyo last year - report Trading in shares of Daiichi Sankyo was suspended yesterday.
News AZ to develop Parkinson's drug with Takeda AstraZeneca could receive up to $400 million from Takeda after approaching the company to jointly develop and market a new treatment for Parkinson’s disease (PD).
News New heart attack data boost AZ’s Brilinta A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients.
News FDA approves Ironwood's gout combination drug Good news for Ironwood, which forecast annual sales of up to $300m, despite black box kidney failure warning.
News AZ signs pact with mRNA specialists Ethris in respiratory di... AstraZeneca has signed a five-year strategic research collaboration with Ethris, an mRNA-based therapeutics company specialising in pulmonary disease.
News AbbVie's Cerevel takeover delivers Parkinson's approval The first drug from AbbVie's $8.7 billion takeover of Cerevel two years ago, Parkinson's disease therapy Juvmo, has won FDA approval.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
